Rapamycin (Sirolimus) Compassionate Use and Expanded Access

What Is Rapamycin (Sirolimus) and Why Are People Seeking Access?

Sirolimus is a macrolide compound first isolated from the bacterium Streptomyces hygroscopicus and approved by the FDA in September 1999 under the brand name Rapamune. [1] The drug inhibits mTOR complex 1, the central nutrient-sensing kinase that regulates cell growth, autophagy, and aging-related pathways. [2]

Approved vs. Off-Label Indications

The FDA has approved sirolimus for two indications: prophylaxis of organ rejection in renal transplant patients aged 13 and older, and treatment of lymphangioleiomyomatosis (LAM). [1] Outside those indications, physicians legally prescribe it off-label. Off-label prescribing is not a legal workaround, it is standard medical practice explicitly protected under federal law and endorsed by the FDA itself. [3]

Longevity researchers have been interested in sirolimus since the landmark 2009 National Institute on Aging Interventions Testing Program study, in which rapamycin extended median lifespan by 28% in male mice and 38% in female mice when started late in life. [4] That single finding accelerated human investigation considerably.

The PEARL Trial and Current Human Evidence

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial (NCT04995991) is enrolling adults aged 50 to 85 to examine whether low-dose sirolimus (5 mg or 10 mg once weekly) affects biological aging markers over 48 weeks. [5] No large randomized controlled trial in healthy adults has yet reported primary outcomes, which is precisely why some patients pursue compassionate-use or expanded-access routes while research matures.

A 2014 study published in Science Translational Medicine (N=218) showed that a short course of the mTOR inhibitor everolimus (a rapamycin analog) at 0.5 mg daily improved influenza vaccine response by 20% in adults over 65, suggesting clinically meaningful immune effects at low doses. [6]

FDA Expanded Access and Compassionate Use: What the Terms Actually Mean

"Compassionate use" and "expanded access" are often used interchangeably, but the FDA uses one formal term: expanded access. It covers three distinct pathways defined under 21 CFR Part 312. [7]

Individual Patient Expanded Access (21 CFR 312.310)

This pathway applies when a single patient has a serious or life-threatening condition, has no comparable alternatives, and the treating physician believes the potential benefit justifies the risk. [7] The physician submits an FDA Form 3926, and the agency typically responds within 24 hours for emergency cases or within 30 days for non-emergency requests. [7]

For sirolimus specifically, individual patient expanded access is rarely the appropriate pathway. The drug is commercially available, generics exist, and licensed physicians can prescribe it off-label today without any FDA submission. Expanded access becomes relevant only if a patient needs an investigational formulation (for example, a novel nanoparticle sirolimus being tested in a trial) that is not commercially sold.

Intermediate-Size Population and Treatment IND Pathways

The intermediate-size pathway (21 CFR 312.315) allows a sponsor to provide an investigational drug to a small group of patients with the same condition. The Treatment IND/Protocol pathway (21 CFR 312.320) is used when widespread access is needed, typically late in a drug's development. [7] Neither pathway applies to commercially available generic sirolimus.

When Expanded Access Is Actually Needed for Sirolimus

Rare scenarios where expanded access may apply include:

• A patient needs an investigational sirolimus nanoformulation (e.g., eRapa or a microencapsulated version) available only within a clinical trial.
• A pediatric patient <13 years old with a condition for which no approved therapy exists and the physician wants to document access formally.
• An international patient in a country where generic sirolimus is not registered and importation requires regulatory documentation.

Outside these narrow scenarios, the standard pathway for off-label sirolimus is a simple prescription from a licensed physician. [3]

How to Get a Legitimate Off-Label Sirolimus Prescription

Finding a Prescribing Physician

Primary care physicians, internists, geriatricians, nephrologists, and telehealth providers who specialize in longevity medicine may prescribe sirolimus off-label. No special DEA schedule or FDA registration is required, sirolimus is not a controlled substance. [1]

The prescribing physician should review your renal function (serum creatinine, eGFR), a complete blood count, a lipid panel, and a fasting glucose before initiating therapy. [8] Sirolimus can raise triglycerides and LDL cholesterol and may impair wound healing, making baseline labs clinically necessary. [8]

Telehealth Platforms in 2026

Several longevity-focused telehealth platforms offer sirolimus consultations with board-certified physicians. These services typically charge a monthly or annual membership fee that covers the physician visit, lab review, and prescription generation. The prescription is then filled at a retail or compounding pharmacy. Always confirm that the prescribing physician holds an active license in your state and that the pharmacy is licensed by your state board of pharmacy.

HealthRX Prescribing Readiness Checklist for Off-Label Sirolimus (2026):

1. Baseline labs: CMP (creatinine, BUN, LFTs), CBC, fasting lipid panel, HbA1c, fasting glucose.
2. Contraindication screen: active infection, planned surgery within 4 weeks, hypersensitivity to sirolimus or excipients.
3. Drug interaction review: strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase sirolimus blood levels by 5- to 15-fold. [8]
4. Informed consent documentation noting off-label status and absence of long-term RCT data in healthy adults.
5. Follow-up labs at 4 weeks and 12 weeks: trough sirolimus level (target 3 to 8 ng/mL for transplant; longevity protocols typically target 1 to 3 ng/mL), lipid panel, CBC.

How to Get Sirolimus Cheaper: A Practical Cost Guide

Brand-name Rapamune (Pfizer) carries a list price exceeding $1,200 per month for a 2 mg daily dose used in transplant patients. [9] Off-label longevity doses are typically lower and less frequent, commonly 1 to 6 mg once weekly, which reduces pill burden, but the list price per tablet remains high without intervention.

Generic Sirolimus

The FDA approved the first generic sirolimus tablets in 2014. [9] Multiple manufacturers now produce 0.5 mg, 1 mg, and 2 mg tablets. At major pharmacy chains with a GoodRx-type discount card, 4 tablets of 1 mg generic sirolimus (covering a once-weekly protocol at 4 mg/week) can cost as little as $40, $80 per month depending on location and pharmacy. Always ask your physician to write the prescription as "generic substitution permitted."

Manufacturer Savings Programs

Pfizer maintains a Rapamune patient savings card for commercially insured patients who meet eligibility criteria. Eligible patients may pay as little as $0, $25 per fill. [10] The savings card does not apply to patients using Medicare, Medicaid, or any other federal healthcare program. Check pfizer.com/rapamune or call the Pfizer helpline directly, as program terms change.

For patients who are uninsured or underinsured, the Pfizer Patient Assistance Program (PAP) may provide Rapamune at no cost to qualifying patients. Income limits and documentation requirements apply. [10]

Pharmacy Discount Tools

Three tools reliably lower generic sirolimus costs:

• GoodRx / Cost Plus Drugs: Mark Cuban's Cost Plus Drugs listed generic sirolimus 1 mg tablets at approximately $0.34 per tablet as of early 2026, making a 4 mg/week protocol roughly $5, $6 per month in drug cost alone (dispensing fees apply).
• NeedyMeds: Aggregates patient assistance programs and disease-specific funds; search "sirolimus" at needymeds.org.
• State pharmaceutical assistance programs: Several states offer supplemental drug coverage for residents above Medicaid income thresholds.

Compounding Pharmacies

PCAB-accredited compounding pharmacies can prepare sirolimus in custom doses (e.g., 0.5 mg capsules for fine titration) or alternative formulations (oral solution, topical). Compounded sirolimus is not FDA-approved and lacks the bioequivalence data of generic tablets. [11] The FDA has noted that compounded versions of commercially available drugs are generally only appropriate when the commercial product does not meet a patient's specific clinical need. [11] Cost may be comparable to or higher than generic tablets depending on the pharmacy.

Insurance Coverage and Prior Authorization

Commercial health insurance rarely covers sirolimus for off-label longevity indications. Coverage is standard for the two FDA-approved indications (transplant rejection prophylaxis and LAM). If your physician documents a covered diagnosis code, the insurer will process the claim normally.

Writing an Effective Prior Authorization Appeal

If an insurer denies coverage for an off-label use, the treating physician can submit a Letter of Medical Necessity (LMN) citing:

• The patient's specific clinical condition and how it relates to mTOR pathway dysregulation.
• Published peer-reviewed evidence (for example, the 2014 everolimus immune-aging trial [6] or data from transplant literature on sirolimus's anti-proliferative effects [2]).
• Failure of or intolerance to approved alternatives when applicable.

Appeals succeed in a minority of cases for longevity indications, but the process costs nothing except physician time.

Can I Use HSA or FSA Funds for Sirolimus?

Yes. Sirolimus purchased with a valid physician prescription qualifies as a medical expense under IRS Publication 502, which governs Health Savings Account (HSA) and Flexible Spending Account (FSA) eligible expenses. [12] The IRS defines eligible medical expenses as "the costs of diagnosis, cure, mitigation, treatment, or prevention of disease." [12]

Practical Steps to Pay With HSA/FSA

1. Obtain a written prescription from your physician, the prescription itself establishes the medical purpose.
2. Pay at the pharmacy counter using your HSA debit card or FSA card directly.
3. Keep the pharmacy receipt and the prescription documentation in case of IRS audit.
4. If your FSA card is not accepted directly (some FSAs require reimbursement submission), submit the itemized pharmacy receipt and the prescription copy to your FSA administrator.

Off-label status does not disqualify a drug from HSA/FSA eligibility. What matters is the prescription and the physician's determination that the drug serves a medical purpose. [12] Supplements and unapproved compounds without a prescription do not qualify. Prescribed sirolimus, even for off-label use, does.

Drug Interactions and Safety Considerations

Sirolimus has a narrow therapeutic index in transplant patients. Off-label longevity protocols use substantially lower doses, but drug interactions remain clinically significant. [8]

CYP3A4 Interactions

Sirolimus is metabolized primarily by CYP3A4 and is a P-glycoprotein substrate. [8] The FDA prescribing information for Rapamune warns that co-administration with strong CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin, erythromycin, diltiazem, grapefruit juice) can increase sirolimus exposure dramatically. [8] Conversely, strong CYP3A4 inducers (rifampin, rifabutin, St. John's Wort) can reduce sirolimus blood levels by up to 82%. [8]

Wound Healing and Surgical Risk

The FDA label notes impaired wound healing with sirolimus. Standard transplant practice holds sirolimus for 2 to 4 weeks before elective surgery and restarts it after wound closure. [8] Patients planning procedures should inform their surgeon and prescribing physician.

Immunosuppression and Infection Risk

At transplant doses (trough targets of 5 to 15 ng/mL), sirolimus produces meaningful immunosuppression. [8] At longevity doses targeting 1 to 3 ng/mL, the immunosuppressive effect is likely smaller but not zero. A 2023 review in Aging Cell noted that low-dose intermittent rapamycin may actually improve certain immune parameters in aged animals, but human data are still limited. [13]

Clinical Trials Offering Structured Access to Sirolimus

Enrolling in a registered clinical trial is a legitimate way to access sirolimus under medical supervision at no drug cost to the participant.

PEARL Trial (NCT04995991)

The PEARL trial, sponsored by the Ora Biomedical/University of Washington group, is studying 5 mg and 10 mg once-weekly sirolimus vs. Placebo in adults aged 50 to 85 over 48 weeks. [5] Primary endpoints include biological age markers and safety. Participants receive drug at no cost, regular lab monitoring, and physician oversight. Check ClinicalTrials.gov for current enrollment status and site locations.

TRIIM-X and Related Studies

Researchers at the Buck Institute and collaborating sites have been investigating combinations of low-dose DHEA, metformin, and growth hormone, with some protocols adding mTOR-targeting agents. While not sirolimus-specific, these trials illustrate the infrastructure that now exists for supervised off-label geriatric pharmacology. [5]

How to Search for Open Trials

Go to clinicaltrials.gov and search "sirolimus" with condition terms "aging," "longevity," or "healthy volunteers." Filter by "Recruiting" status and your geographic region. The site lists contact information for each trial coordinator.

Regulatory Outlook: Will Rapamycin Get a Longevity Indication?

The FDA does not currently recognize "aging" as a disease indication, which means no drug can be approved specifically for longevity. The agency's Hematology and Oncology Products division has acknowledged exploratory discussions about aging as a biological endpoint, but no formal guidance exists as of early 2026. [14]

The Targeting Aging with Metformin (TAME) trial's regulatory framework, in which the FDA agreed to accept biological aging endpoints, may eventually create a template for future mTOR inhibitor trials. [14] Until a longevity-specific approval exists, sirolimus will remain an off-label product for this use, and expanded access pathways will remain largely irrelevant to its access.